Isavuconazole for the Treatment of Fungal Infections: A Real-life Experience From the Fungal Infection Network of Switzerland (FUNGINOS)-Reference-Cited by-同舟云学术

Isavuconazole for the Treatment of Fungal Infections: A Real-life Experience From the Fungal Infection Network of Switzerland (FUNGINOS)

Published:2024-04-26 Issue:5 Volume:11 Page:
ISSN:2328-8957
Container-title:Open Forum Infectious Diseases
language:en
Short-container-title:

Author:

Couchepin Jade¹,Reinhold Ilana²^ORCID,Kronig Ilona³,Guidi Monia⁴⁵⁶^ORCID,Buclin Thierry⁴^ORCID,Schreiber Peter W²,Neofytos Dionysios³^ORCID,Lamoth Frederic¹⁷^ORCID, ,Albrich Werner,Berezowska Sabina,Berger Christoph,Bergeron Anne,Bochud Pierre-Yves,Boggian Katia,Conen Anna,Emonet Stéphane,Erard Véronique,Garzoni Christian,Goldenberger Daniel,Hinic Vladimira,Hirzel Cedric,Khanna Nina,Kohns Malte,Kronenberg Andreas,Lamoth Frederic,Landis Basile,Marchetti Oscar,Mühlethaler Konrad,Müller Linda,Neofytos Dionysios,Osthoff Michael,Pagani Jean-Luc,Quiblier Chantal,Reinhold Ilana,Riat Arnaud,Rupp Niels,Sanglard Dominique,Schreiber Peter Werner,Siegemund Martin,Walti Laura

Affiliation:

1. Infectious Diseases Service, Department of Medicine, Lausanne University Hospital and University of Lausanne , Lausanne , Switzerland

2. Department of Infectious Diseases and Hospital Epidemiology, University Hospital of Zurich and University of Zurich , Zurich , Switzerland

3. Division of Infectious Diseases, University Hospital of Geneva , Geneva , Switzerland

4. Service of Clinical Pharmacology, Lausanne University Hospital and University of Lausanne , Lausanne , Switzerland

5. Institute of Pharmaceutical Sciences of Western Switzerland, University of Geneva , Geneva , Switzerland

6. Centre for Research and Innovation in Clinical Pharmaceutical Sciences, Lausanne University Hospital and University of Lausanne , Lausanne , Switzerland

7. Institute of Microbiology, Lausanne University Hospital and University of Lausanne , Lausanne , Switzerland

Abstract

Abstract This analysis of 116 isavuconazole therapy courses shows that hepatic test disturbances (HTDs) were relatively frequent (29% of cases) but rarely led to treatment interruption (5%). Importantly, patients with baseline HTDs, including those attributed to a first-line triazole, did not exhibit a higher risk of subsequent HTD under isavuconazole therapy.

Funder

Pfizer

Publisher

Oxford University Press (OUP)

Link

https://academic.oup.com/ofid/advance-article-pdf/doi/10.1093/ofid/ofae223/57339353/ofae223.pdf

Reference25 articles.

1. Prospective surveillance for invasive fungal infections in hematopoietic stem cell transplant recipients, 2001–2006: overview of the Transplant-Associated Infection Surveillance Network (TRANSNET) database;Kontoyiannis;Clin Infect Dis,2010

2. Invasive fungal infections among organ transplant recipients: results of the Transplant-Associated Infection Surveillance Network (TRANSNET);Pappas;Clin Infect Dis,2010

3. Pulmonary aspergillosis: diagnosis and treatment;Lamoth;Eur Respir Rev,2022

4. Therapeutic challenges of non-Aspergillus invasive mold infections in immunosuppressed patients;Lamoth;Antimicrob Agents Chemother,2019

5. Triazole antifungal agents in invasive fungal infections: a comparative review;Lass-Flörl;Drugs,2011